Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Long-term Activity Ratios (Summary)

Abiomed Inc., long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016
Net fixed asset turnover
Total asset turnover
Equity turnover

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).


The analysis of the financial ratios over the reported periods reveals several noteworthy trends concerning the company's asset efficiency and equity utilization.

Net Fixed Asset Turnover
This ratio, which measures the revenue generated per unit of net fixed assets, exhibits relatively stable performance with slight fluctuations over the observed periods. Initially, values hovered slightly above 5.0 from mid-2017 through early 2020, peaking around 5.32 in late 2018 and early 2019. A notable decline appears in mid-2020, hitting a low near 4.3 in early 2021, indicating reduced efficiency in using fixed assets during that period. However, from mid-2021 onwards, there is a recovery trend, with the ratio increasing steadily to about 5.5 by late 2022, suggesting improved asset utilization efficiency towards the latter periods.
Total Asset Turnover
This ratio, indicating total revenue generated per total assets, displays a declining trend over the time frame. Starting at approximately 0.81 in early 2017, it gradually decreased with minor intermittent recoveries, falling to around 0.57 by early 2021. Although there is a subtle rebound to roughly 0.64 in late 2021, the ratio remains below earlier levels and trends slightly downward again toward the end of the series, registering near 0.62. This pattern points to a diminishing efficiency in leveraging total assets to generate revenue over the course of the periods.
Equity Turnover
This ratio, reflecting revenue generated per unit of shareholder equity, follows a similar downward trajectory as total asset turnover. Moving from a peak of nearly 0.99 before mid-2017, the ratio steadily declines over the years, reaching lows near 0.64 in early 2021. A modest recovery is observed afterward, rising close to 0.7 by late 2022. The sustained reduction indicates decreasing revenue generation efficiency relative to equity, though the late-period improvement may signal preliminary recovery efforts in capital utilization.

Overall, the data indicates that while the company managed to maintain and ultimately improve the efficiency of fixed asset use after a temporary setback, the broader efficiency in utilizing total assets and equity to generate revenue has generally declined with some signs of stabilization and moderate recovery in the final periods. The distinct divergence between the recovering net fixed asset turnover and the still subdued total asset and equity turnover ratios suggests potential shifts in the asset base composition or revenue streams that merit further strategic examination.


Net Fixed Asset Turnover

Abiomed Inc., net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016
Selected Financial Data (US$ in thousands)
Revenue
Property and equipment, net
Long-term Activity Ratio
Net fixed asset turnover1
Benchmarks
Net Fixed Asset Turnover, Competitors2
Abbott Laboratories
CVS Health Corp.
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).

1 Q2 2023 Calculation
Net fixed asset turnover = (RevenueQ2 2023 + RevenueQ1 2023 + RevenueQ4 2022 + RevenueQ3 2022) ÷ Property and equipment, net
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The revenue demonstrates a generally positive growth trend over the observed periods. Starting from approximately 103 million US dollars in June 2016, it increases steadily with some fluctuations, peaking at around 277 million US dollars by June 2022. Notably, a decline is observable around mid-2020, coinciding with a drop to about 165 million US dollars in June 2020, which may be indicative of external challenging factors during this interval. However, the revenue recovers in the subsequent quarters, continuing an upward trajectory through to mid-2022.

The net book value of property and equipment shows a consistent upward trend, rising from roughly 26 million US dollars in June 2016 to about 198 million US dollars by June 2022. This indicates ongoing investment and asset accumulation over the periods, with a steady incremental increase quarter over quarter. The growth pace appears relatively stable without significant abrupt changes, suggesting continuous capital expenditures or asset acquisitions supporting operational capacity.

The net fixed asset turnover ratio exhibits some variability but displays a mild declining trend after peaking in earlier years. Initially, from the first available measurement near March 2017, the ratio hovers around 5.0, with slight fluctuations. However, from 2019 onwards, a downward movement is noticeable, dipping below 4.7 in early 2021. Following this decrease, the ratio begins to recover moderately, returning to values around 5.3 to 5.5 by the last recorded quarters in 2022.

Revenue
Shows consistent overall growth with a temporary drop around mid-2020, recovering thereafter to reach record levels by mid-2022.
Property and Equipment, Net
Steady increase throughout all periods, reflecting ongoing investment in fixed assets and enhanced operational infrastructure.
Net Fixed Asset Turnover Ratio
Initially stable at roughly 5.0, declines from 2019 into early 2021, then shows a partial recovery in late 2021 and 2022, indicating changes in asset utilization efficiency over time.

Total Asset Turnover

Abiomed Inc., total asset turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016
Selected Financial Data (US$ in thousands)
Revenue
Total assets
Long-term Activity Ratio
Total asset turnover1
Benchmarks
Total Asset Turnover, Competitors2
Abbott Laboratories
CVS Health Corp.
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).

1 Q2 2023 Calculation
Total asset turnover = (RevenueQ2 2023 + RevenueQ1 2023 + RevenueQ4 2022 + RevenueQ3 2022) ÷ Total assets
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The financial data indicates a general upward trend in revenue from June 2016 through September 2022, with fluctuations in certain quarters. Revenue increased from approximately $103 million in mid-2016 to a peak exceeding $277 million by late 2022. Notable acceleration periods include the intervals from late 2017 through early 2019 and again from late 2020 through 2021, which saw substantial revenue growth. However, there are periods of slight declines, such as the third quarter of 2020, where revenue dropped to around $165 million, indicating possible external impacts or operational challenges.

Total assets exhibited consistent growth over the same period, rising from about $429 million in mid-2016 to nearly $1.7 billion by the third quarter of 2022. This steady increase in assets reflects ongoing investments and expansion of the company's asset base. The growth rate of total assets appears relatively smooth, without sharp contractions, suggesting a stable accumulation of resources.

The total asset turnover ratio, representing the efficiency with which the company uses its assets to generate revenue, shows a declining trend over the examined timeframe. Starting at approximately 0.81 in early 2017, the ratio gradually decreased to around 0.62 by late 2022. This downward movement suggests that revenue growth has not kept pace with asset growth, indicating a potential decrease in asset utilization efficiency.

Overall, the data reveals a company experiencing robust growth in revenue and asset accumulation, accompanied by a gradual decline in the efficiency of asset usage. Continuous monitoring of asset turnover alongside revenue and asset expansion will be essential to evaluate the effectiveness of capital deployment and operational performance moving forward.


Equity Turnover

Abiomed Inc., equity turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016
Selected Financial Data (US$ in thousands)
Revenue
Stockholders’ equity
Long-term Activity Ratio
Equity turnover1
Benchmarks
Equity Turnover, Competitors2
Abbott Laboratories
CVS Health Corp.
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).

1 Q2 2023 Calculation
Equity turnover = (RevenueQ2 2023 + RevenueQ1 2023 + RevenueQ4 2022 + RevenueQ3 2022) ÷ Stockholders’ equity
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals several notable trends over the periods under consideration.

Revenue Trends
Revenue exhibited an overall upward trajectory, increasing from approximately 103 million US dollars in mid-2016 to nearly 278 million US dollars by late 2022. This growth was generally consistent, with occasional fluctuations. Notably, revenue experienced a temporary decline around mid-2020, dropping to about 165 million US dollars, possibly reflecting external market or operational challenges during that period. Subsequently, revenue rebounded and continued its upward trend through 2021 into 2022, reaching new highs.
Stockholders’ Equity Behavior
Stockholders’ equity demonstrated a steady increase throughout the timeframe, beginning near 377 million US dollars in June 2016 and rising to approximately 1.54 billion US dollars by September 2022. This growth indicates a strengthening financial position with accumulated retained earnings or capital contributions contributing to increased equity. There were no significant declines observed, suggesting stable or positive overall equity management.
Equity Turnover Ratio Movement
The equity turnover ratio, which measures how efficiently the company uses its equity to generate revenue, showed a declining trend from the first available data point in March 2017 onward. Starting from roughly 0.99, the ratio decreased steadily to about 0.69 by the third quarter of 2022. This decline implies that while equity increased substantially, revenue generation relative to equity growth slowed over time. The reduced efficiency in equity utilization might suggest increasing capital base without proportional revenue gains or a shift in business dynamics.

In summary, the data point to substantial revenue growth and strong equity accumulation, albeit accompanied by a gradual reduction in the efficiency of equity use to generate revenue. The temporary revenue dip observed in mid-2020 merits further investigation to understand underlying causes. Overall, the financial position appears robust, with increasing capital and revenue bases, though operational efficiency as reflected by equity turnover requires attention.